Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
19.47
-0.52 (-2.60%)
At close: Aug 26, 2026, 4:00 PM EDT
19.75
+0.28 (1.44%)
After-hours: Aug 26, 2026, 7:56 PM EDT
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Software Products and Services | 178.24M | 186.24M | 199.50M | 209.92M | 200.94M | 195.80M | 180.40M | 169.40M | |||||||
| Software Products and Services Growth | -11.30% | -4.88% | 10.59% | 23.92% | 20.74% | 22.09% | 13.34% | 22.52% | |||||||
| Drug Discovery | 77.43M | 68.66M | 56.37M | 47.12M | 37.06M | 34.77M | 27.22M | 24.02M | |||||||
| Drug Discovery Growth | 108.96% | 97.47% | 107.09% | 96.16% | 8.10% | 23.37% | -52.72% | -60.67% | |||||||
| Contributions | 3.36M | - | - | - | - | - | - | - |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Software Products and Services | 21.30M | 26.88M | 27.51M | |||||||||||||||
| Software Products and Services Growth | -21.45% | -2.04% | 1.09% | |||||||||||||||
| Drug Discovery | 12.30M | 11.71M | 12.98M | |||||||||||||||
| Drug Discovery Growth | -4.45% | 8.73% | 63.40% | |||||||||||||||
| Software Contribution | - | 12.14M | 15.99M | 18.18M | 16.37M | 11.86M | 8.02M | 3.12M | 1.80M | - | - | - | ||||||
| Software Contribution Growth | - | 2.39% | 99.45% | 481.91% | 809.61% | 558.89% | 345.33% | 73.56% | - | - | - | - |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Discovery Services Customer Contracts | 76.46M | 67.40M | 54.76M | 45.32M | 35.12M | 32.69M | 25.14M | 21.97M | |||||||
| Drug Discovery Services Customer Contracts Growth | 117.71% | 106.21% | 117.79% | 106.30% | 10.16% | 27.64% | -54.05% | -62.27% | |||||||
| Drug Discovery Contribution | 1.42M | 1.26M | 1.61M | 1.76M | 1.89M | 2.04M | 2.03M | 2.02M | |||||||
| Drug Discovery Contribution Growth | -24.81% | -38.30% | -20.78% | -13.29% | -20.12% | -19.95% | -28.03% | -29.72% |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 158.18M | 154.71M | 152.96M | 131.30M | 124.59M | 121.24M | 114.87M | 133.14M | |||||||
| United States Growth | 26.97% | 27.61% | 33.16% | -1.39% | -12.05% | -10.14% | -29.08% | -8.89% | |||||||
| EMEA | 71.98M | 72.25M | 75.16M | 91.28M | 80.70M | 81.54M | 65.65M | 33.86M | |||||||
| EMEA Growth | -10.81% | -11.39% | 14.49% | 169.56% | 148.50% | 176.37% | 125.33% | 22.28% | |||||||
| APAC | 27.60M | 26.78M | 26.18M | 32.70M | 31.23M | 26.38M | 25.80M | 25.18M | |||||||
| APAC Growth | -11.64% | 1.54% | 1.47% | 29.87% | 22.62% | 14.69% | 5.02% | -19.14% | |||||||
| Rest of World | 1.27M | 1.16M | 1.56M | 1.67M | 1.40M | 1.35M | 1.22M | 1.16M | |||||||
| Rest of World Growth | -9.01% | -13.53% | 28.16% | 44.18% | 35.43% | 25.94% | 21.68% | - |